GelMEDIX, a biotechnology company developing regenerative therapies to restore vision, and Catalent, a leader in enabling the development and supply of better treatments for patients worldwide, have announced a global partnership to access Catalent’s GMP-induced pluripotent stem cells (iPSC) and Catalent’s cell therapy manufacturing expertise and capabilities to support the development and clinical manufacturing of GelMEDIX’s iPSC-derived cell therapies to treat ocular and retinal diseases.
Under the agreement, GelMEDIX will partner with Catalent for iPSC and cell therapy development and will access Catalent’s proprietary, off-the-shelf, GMP-compliant iPSC lines and Catalent’s GMP iPSC and iPSC-derived cell therapy manufacturing capabilities.
Catalent, as a global leader in the development and manufacturing of human iPSCs and iPSC-derived cells, will also support the process development, analytical development, process scale-up and GMP manufacturing of GelMEDIX’s iPSC-derived therapies, from early development through all clinical stages.
